Arielle Gurwitch
Senior Director, US Public Policy Eli Lilly & Co.
Arielle Gurwitch joined Eli Lilly in December of 2025 as Senior Director, Public Policy. In this role, she is responsible for leading policy work in new and emerging technologies and therapeutic areas to Lilly – with a focus on gene therapy, precision medicine and new modalities in cancer care. Prior to joining Lilly, Arielle served as Director, US Policy and Advocacy at Iovance Biotherapeutics where she was part of a team that helped launch the first cell therapy in solid tumors. Arielle previously held various federal policy roles at AbbVie, the Biotechnology Innovation Organization, and JDRF.
Seminars
Thursday 16th July 2026
Navigating Access & Policy Barriers for the Next Generation of Cell & Gene Therapies
11:00 am
- Addressing access obstacles and new considerations in emerging indications to expand CAR‑T cell therapy and gene therapy delivery beyond oncology and smaller indications
- Policy challenges and opportunities to broaden treatment reach across the US outside major academic centres and improving patient access pathways
- Identifying key areas of reimbursement and access policy shaping that will enable future patients to receive innovative therapies
